|
|
Prepublished online as a Blood First Edition Paper on May 8, 2003; DOI 10.1182/blood-2002-10-3096.
 Previous Article | Table of Contents | Next Article 
Blood, 15 August 2003, Vol. 102, No. 4, pp. 1276-1281
HEMATOPOIESIS
Mithramycin induces fetal hemoglobin production in normal and thalassemic human erythroid precursor cells
Eitan Fibach,
Nicoletta Bianchi,
Monica Borgatti,
Eugenia Prus, and
Roberto Gambari
From the Department of Hematology, Hadassah University Hospital, Jerusalem, Israel; Department of Biochemistry and Molecular Biology, University of Ferrara, Italy; and Laboratory for the Development of Pharmacological and Pharmacogenomic Therapy of Thalassemia, Biotechnology Center, University of Ferrara, Italy.
We report in this paper that the DNA-binding drug mithramycin is a potent inducer of  -globin mRNA accumulation and fetal hemoglobin (HbF) production in erythroid cells from healthy human subjects and  -thalassemia patients. Erythroid precursors derived from peripheral blood were grown in 2-phase liquid culture. In this procedure, early erythroid progenitors proliferate and differentiate during phase 1 (in the absence of erythropoietin) into late progenitors. In phase 2, in the presence of erythropoietin, the latter cells continue their proliferation and mature into Hb-containing orthochromatic normoblasts. Compounds were added on days 4 to 5 of phase 2 (when cells started to synthesize Hb), and cells were harvested on day 12. Accumulation of mRNAs for -globin, -globin,  -globin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and -actin were measured by real-time quantitative reverse transcription–polymerase chain reaction (RT-PCR); induction of HbF was analyzed by high-performance liquid chromatography (HPLC) and, at cellular level, by flow cytometry. We demonstrated that mithramycin was able to up-regulate preferentially -globin mRNA production and to increase HbF accumulation, the percentage of HbF-containing cells, and their HbF content. Mithramycin was more effective than hydroxyurea, being, in addition, not cytotoxic. This was shown by the lack of cytotoxicity on erythroid and myeloid in vitro primary cell cultures treated with mithramycin at concentrations effective for HbF induction. These results are of potential clinical significance because an increase of HbF alleviates the symptoms underlying -thalassemia and sickle cell anemia. The results of this report suggest that mithramycin and its analogs warrant further evaluation as potential therapeutic drugs.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
N. Bianchi, C. Zuccato, I. Lampronti, M. Borgatti, and R. Gambari
Fetal Hemoglobin Inducers from the Natural World: A Novel Approach for Identification of Drugs for the Treatment of {beta}-Thalassemia and Sickle-Cell Anemia
Evid. Based Complement. Altern. Med.,
June 1, 2009;
6(2):
141 - 151.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Lampronti, M. T.H. Khan, M. Borgatti, N. Bianchi, and R. Gambari
Inhibitory Effects of Bangladeshi Medicinal Plant Extracts on Interactions between Transcription Factors and Target DNA Sequences
Evid. Based Complement. Altern. Med.,
September 1, 2008;
5(3):
303 - 312.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Bataller, C. Mendez, J. A. Salas, and J. Portugal
Mithramycin SK modulates polyploidy and cell death in colon carcinoma cells
Mol. Cancer Ther.,
September 1, 2008;
7(9):
2988 - 2997.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Hsieh, N. S. Linde, A. Wynter, M. Metzger, C. Wong, I. Langsetmo, A. Lin, R. Smith, G. P. Rodgers, R. E. Donahue, et al.
HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques
Blood,
September 15, 2007;
110(6):
2140 - 2147.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Barcelo, C. Scotta, M. Ortiz-Lombardia, C. Mendez, J. A. Salas, and J. Portugal
Entropically-driven binding of mithramycin in the minor groove of C/G-rich DNA sequences
Nucleic Acids Res.,
April 1, 2007;
35(7):
2215 - 2226.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Wu, J. Vieira, N. Fiore, P. Banerjee, M. Sieburg, R. Rochford, W. Harrington Jr, and G. Feuer
KSHV/HHV-8 infection of human hematopoietic progenitor (CD34+) cells: persistence of infection during hematopoiesis in vitro and in vivo
Blood,
July 1, 2006;
108(1):
141 - 151.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Albertini, A. Jain, S. Vignati, S. Napoli, A. Rinaldi, I. Kwee, M. Nur-e-Alam, J. Bergant, F. Bertoni, G. M. Carbone, et al.
Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy.
Nucleic Acids Res.,
January 1, 2006;
34(6):
1721 - 1734.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-H. Hou and A. H.-J. Wang
Mithramycin forms a stable dimeric complex by chelating with Fe(II): DNA-interacting characteristics, cellular permeation and cytotoxicity
Nucleic Acids Res.,
March 1, 2005;
33(4):
1352 - 1361.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Chakalova, C. S. Osborne, Y.-F. Dai, B. Goyenechea, A. Metaxotou-Mavromati, A. Kattamis, C. Kattamis, and P. Fraser
The Corfu {delta}{beta} thalassemia deletion disrupts {gamma}-globin gene silencing and reveals post-transcriptional regulation of HbF expression
Blood,
March 1, 2005;
105(5):
2154 - 2160.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.-H. Hou, H. Robinson, Y.-G. Gao, and A. H.-J. Wang
Crystal structure of the [Mg2+-(chromomycin A3)2]-d(TTGGCCAA)2 complex reveals GGCC binding specificity of the drug dimer chelated by a metal ion
Nucleic Acids Res.,
April 23, 2004;
32(7):
2214 - 2222.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Vadolas, H. Wardan, M. Orford, R. Williamson, and P. A. Ioannou
Cellular genomic reporter assays for screening and evaluation of inducers of fetal hemoglobin
Hum. Mol. Genet.,
January 15, 2004;
13(2):
223 - 233.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
